Buscar en
Annals of Hepatology
Toda la web
Inicio Annals of Hepatology
Journal Information
Issue
Vol. 22.
(May - June 2021)
Editorial Board
Ann Hepatol. 2021;22C:100353
Open access
Editorial
Latin America and chronic diseases: A perfect storm during the COVID-19 pandemic
Antonio Pizuorno, Nora A. Fierro
Ann Hepatol. 2021;22C:100332
Open access
Open Article
Concise reviews
Usefulness of neutrophil-to-lymphocyte ratio (NLR) as a prognostic predictor after treatment of hepatocellular carcinoma." Review article
Mohamad Mouchli, Shravani Reddy, Miranda Gerrard, Lisa Boardman, Marrieth Rubio
Ann Hepatol. 2021;22C:249
Open access
Infected hepatic echinococcosis. Clinical, therapeutic, and prognostic aspects. A systematic review
Sergio Castillo, Carlos Manterola, Luis Grande, Claudio Rojas
Ann Hepatol. 2021;22C:237
Open access
An Integrated Review of the Hepatorenal Syndrome
Alicia S. Ojeda-Yuren, Eira Cerda-Reyes, Maria R. Herrero-Maceda, Graciela Castro-Narro, Salvatore Piano
Ann Hepatol. 2021;22C:236
Open access
Original articles
Turnera diffusa extract attenuates profibrotic, extracellular matrix and mitochondrial markers in activated human hepatic stellate cells (HSC)
Diana Raquel Rodríguez-Rodríguez, Sonia Amelia Lozano-Sepulveda, Cecilia Delgado-Montemayor, Noemí Waksman, Paula Cordero-Perez, Ana María Rivas-Estilla
Ann Hepatol. 2021;22C:281
Open access
Hepatitis B virus in Lao dentists: A cross-sectional serological study
Bouasone Mangkara, Kinnaly Xaydalasouk, Phetsavanh Chanthavilay, Sengchanh Kounnavong, Somphou Sayasone, Claude P. Muller, Phimpha Paboriboune, Antony P. Black
Ann Hepatol. 2021;22C:282
Open access
Predictors of do-not-resuscitate order utilization in decompensated cirrhosis hospitalized patients: A nationwide inpatient cohort study
Savan Kabaria, Kapil Gupta, Abhishek Bhurwal, Anish V. Patel, Vinod K. Rustgi
Ann Hepatol. 2021;22C:284
Open access
FibroMeter scores for the assessment of liver fibrosis in patients with autoimmune liver diseases
Kalliopi Zachou, Vasiliki Lygoura, Pinelopi Arvaniti, Georgios Giannoulis, Nikolaos K. Gatselis, George K. Koukoulis, George N. Dalekos
Ann Hepatol. 2021;22C:285
Open access
Impact of Brazilian expanded criteria for liver transplantation in patients with hepatocellular carcinoma: a multicenter study
Aline Lopes Chagas, Angelo A. Mattos, Márcio A. Diniz, Guilherme E.G. Felga, Ilka F.S.F. Boin, Rita C. M.A. Silva, Renato F. Silva, José H.P. Garcia, Agnaldo S. Lima, Júlio C.U. Coelho, Paulo L. Bittencourt, Venâncio A.F. Alves, Luiz Augusto Carneiro D'Albuquerque, Flair J. Carrilho
Ann Hepatol. 2021;22C:100294
Highlights

  • Largest Brazilian study analyzing post-transplant outcomes in HCC patients.

  • Post-transplant overall survival in HCC patients was 63% over five years.

  • HCC recurrence was observed in 8% of patients submitted to liver transplantation.

  • Patients within Brazilian expanded criteria had lower survival than Milan Criteria.

  • Brazilian criteria was inferior to Milan Criteria to predict tumor recurrence.

Open access
Post-liver transplant outcomes in patients with major psychiatric diagnosis in the United States
Satish K. Kedia, Bilal Ali, Yu Jiang, Hassan Arshad, Sanjaya K. Satapathy, Humberto C. Gonzalez
Ann Hepatol. 2021;22C:100311
Open access
Standardization of conventional chemoembolization for hepatocellular carcinoma
Matteo Renzulli, Giuliano Peta, Francesco Vasuri, Giovanni Marasco, Daniele Caretti, Laura Bartalena, Daniele Spinelli, Emanuela Giampalma, Antonietta D’Errico, Rita Golfieri
Ann Hepatol. 2021;22C:278
Open access
Health-related quality of life in Cuban patients with chronic liver disease: A real-world experience
Marlen I. Castellanos-Fernández, Susana A. Borges-González, Maria Stepanova, Mirtha E. Infante-Velázquez, Caridad Ruenes-Domech, Sila M. González-Suero, Zaily Dorta-Guridi, Enrique R. Arus-Soler, Andrei Racila, Zobair M. Younossi
Ann Hepatol. 2021;22C:277
Highlights

  • Patient reported outcomes (PROs) are important to understanding the impact a disease from the patients’ point of view.

  • Chronic liver disease (CLD) can carry a high clinical and PRO burden.

  • PRO data are few among patients with CLD who reside in the Latin America and the Caribbean areas.

  • Using valid and reliable PRO instruments, we quantified PROs for patients with CLD living in Cuba.

  • We determined that patients from Cuba with hepatitis C virus and autoimmune liver disease had the worst PRO scores most likely related to more severe underlying liver disease (fibrosis) and/or to extrahepatic manifestations (fatigue, abdominal pain, anxiety, and depression).

Open access
Long noncoding RNA LINC01189 is associated with HCV-hepatocellular carcinoma and regulates cancer cell proliferation and chemoresistance through hsa-miR-155-5p
Ying Yao, Fang Shu, Fang Wang, Xiaoqiang Wang, Zhengshe Guo, Haili Wang, Lu Li, Haigang Lv
Ann Hepatol. 2021;22C:269
Open access
Renal and brain failure predict mortality of patients with acute-on-chronic liver failure admitted to the intensive care unit
Osvely Méndez-Guerrero, Daniel A. Calle-Rodas, Eduardo Cervantes-Alvarez, Elisa Alatorre-Arenas, Juanita Pérez-Escobar, Nalu Navarro-Alvarez, Aldo Torre
Ann Hepatol. 2021;22C:270
Open access
Unexpected findings of hepatitis B and delta infection in northeastern Brazil: A public health alert
Jomar Diogo Costa Nunes, Diego Luz Felipe da Silva, Lena Maria Barros Fonseca, Ilana Mirian Almeida Felipe, Beatriz Rossetti Ferreira, Rodrigo de Carvalho Santana, Ana de Lourdes Candolo Martinelli, Antônio Augusto Moura da Silva, João Renato Rebello Pinho, Michele Soares Gomes Gouvêa, Max Diego Cruz Santos, Thais Feres Moreira Lima, Ingrid de Campos Albuquerque, Marinilde Teles Souza, Maria Josélia Diniz Moraes, Arlene de Jesus Mendes Caldas, Letícia Alana Barros Souza, Camila Maria Pinheiro de Mello e Silva, Adalgisa de Souza Paiva Ferreira
Ann Hepatol. 2021;22C:272
Open access
Clinical practice guidelines
Brazilian Society of Hepatology and Brazilian College of Radiology practice guidance for the use of elastography in liver diseases
Ana Carolina Cardoso, Cristiane A. Villela-Nogueira, Cláudio de Figueiredo-Mendes, Hilton Leão Filho, Rogério Augusto Pinto Silva, Cristiane Valle Tovo, Hugo Perazzo, Antonio Carlos Matteoni, Roberto José de Carvalho-Filho, Paulo Lisboa Bittencourt
Ann Hepatol. 2021;22C:100341
Open access
Case report
A fat containing combined neuroendocrine carcinoma and hepatocellular carcinoma in the liver: A case report
Atsuyuki Ikeda, Kentaro Aoki, Tsuyoshi Terashima, Yoshio Itokawa, Hiroyuki Kokuryu
Ann Hepatol. 2021;22C:183
Open access
Tips for TIPS: A combined percutaneous and transjugular approach for intrahepatic portosystemic shunt placement after liver transplant
Ilaria Lenci, Benedetto Neri, Daniele Morosetti, Martina Milana, Giampiero Palmieri, Giuseppe Tisone, Antonio Orlacchio, Mario Angelico, Leonardo Baiocchi
Ann Hepatol. 2021;22C:162
Open access
Letters to the editor
Usefulness of collagen type IV in the detection of significant liver fibrosis in nonalcoholic fatty liver disease
Chaoli Chen, Xiaofei Li, Wu Guolin
Ann Hepatol. 2021;22C:100300
Open access
Non-invasive diagnosis of non-alcoholic fatty liver disease using an algorithm combining clinical indexes and ultrasonographic measures
Monica C. Preciado-Puga, Yeniley Ruiz-Noa, Juana R. Garcia-Ramirez, Benjamin Jordan-Perez, Serafin Garnelo-Cabañas, Maria L. Lazo de la Vega-Monroy, Karen I. Gutierrez-Aguirre, Lorena R. Ibarra-Reynoso
Ann Hepatol. 2021;22C:100335
Open access
Reply to: Association of liver steatosis and fibrosis with clinical outcomes in patients with SARS-CoV-2 infection (COVID-19)
Ivan López-Mendez, Graciela Castro-Narro
Ann Hepatol. 2021;22C:100326
Open access
Open Article
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos